Ultime notizie per Kindly MD Inc (NASDAQ:KDLY) Azioni

Kindly MD Inc

Kindly MD Inc Warrants (15/05/2029)

WIIM

ULTA

Ulta shares are trading higher after the company reported better-than-expected Q1 financial results and raised guidance.

REGN

Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study didd not.

Telsey Advisory Group analyst Dana Telsey maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Market Perform and maintains $12 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on American Eagle Outfitters, Maintains $12 Price Target

Gap shares are trading lower after the company reported Q1 financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.

SCNI

Scinai Immunotherapeutics Reports Q1 Revenues Of $586,000; Exits Quarter With Cash & Equivalents Worth $1.01M

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), announced today that the Company and Dr. Raza Bokhari, Company's former Executive Chairman and Chief Executive Officer (CEO), have reached a global settlement agreement (the "agreement") to settle all and any disputes originating out of the proxy contest originally commencing January 2021. Mr. Zeeshan Saeed, Co-Chairman &amp; CEO, and Mr. Anthony Durkacz, Co-Chairman of the Company, also signed the agreement in their personal capacity.
The agreement brings to a complete and final closure all outstanding issues and prevents any future litigation in various courts in Canada and the United States. The payment of $2,350,000 USD from Dr. Bokhari to Quantum BioPharma Ltd. (Formerly FSD Pharma Inc.) satisfies all outstanding monetary claims by the Company, Zeeshan Saeed, Anthony Durkacz and other current or former employees, officers, Directors, affiliates or agents of the Company as well as any and all legal and monetary claims by Dr. Bokhari. The $2,350,000 USD is a non-dilutive injection of cash into Quantum BioPharma.
In the agreement, Dr. Raza Bokhari, Quantum BioPharma Ltd, Zeeshan Saeed and Anthony Durkacz did not admit to any wrongdoing. All parties agreed that at all times they were acting in the best interest of the corporation and the shareholders.

Legal

CSE:QNTM

QNTM

Quantum BioPharma Ends Legal Fight With Former CEO, Receives $2.35M Settlement

<a href="https://www.bloomberg.com/news/articles/2025-05-30/china-preps-70-billion-in-new-capital-to-supercharge-investment" title="https://www.bloomberg.com/news/articles/2025-05-30/china-preps-70-billion-in-new-capital-to-supercharge-investment">https://www.bloomberg.com/news/articles/2025-05-30/china-preps-70-billion-in-new-capital-to-supercharge-investment</a>

Macro Economic Events

Global

Economics

Bloomberg: China Plans To Allocate $70B Of Capital That Could Be Leveraged Up To Fast Track New Infrastructure Projects

Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.10) by 910 percent. This is a 27.85 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $45.75 million which missed the analyst consensus estimate of $49.92 million by 8.36 percent. This is a 15.29 percent decrease over sales of $54.00 million the same period last year.

Earnings

Earnings Misses

Canopy Growth Q4 EPS $(1.01) Misses $(0.10) Estimate, Sales $45.75M Miss $49.92M Estimate

Ascendiant Capital analyst Edward Woo maintains Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) with a Buy and raises the price target from $60 to $62.

VERB

Ascendiant Capital Maintains Buy on Verb Technology Co, Raises Price Target to $62

Laboratory Corporation Of America Holdings

Labcorp Expands Oncology Portfolio With New Tests For Solid And Blood Cancers; Reveals Expansion Of Capabilities To OmniSeq INSIGHT

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
&nbsp;
The CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
Updated results from the pilot phase indicate that four of eleven patients remained progression free after more than one year. Two patients underwent definitive treatment for mPDAC: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response. An analysis of pre- and on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination. In addition, patients achieving a partial response were found to have higher pre-treatment proportions of CXCL12-producing cancer associated fibroblasts, a potential marker of response.

BLRX

BioLineRx Reports Long-Term Tumor Control in Some Patients From New Pancreatic Cancer Combo Trial

Modine To Acquire L.B. White, Total Consideration Based On Enterprise Value Of $112M; L.B. White Expects To Report Revenue Of $73.5M For 2025 Fiscal Year Ending May 31

BRKR

Bruker Unveils timsMetabo Mass Spectrometer With Advanced TIMS 'MoRE' Scan-Mode

Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).
Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors.
"With the first participant now successfully enrolled, commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy."
"Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate," said James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and&nbsp;Allied Health&nbsp;at the&nbsp;University of North Carolina School of Medicine. "Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study."
The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.

RNAC

Cartesian Begins Phase 3 Trial of New Cell Therapy for Myasthenia Gravis Without Chemo

Needham analyst Quinn Bolton maintains Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Buy and lowers the price target from $110 to $90.

AMBA

Needham Maintains Buy on Ambarella, Lowers Price Target to $90

Biotech

Health Care

General

BCRX

Biocryst Pharmaceuticals Announced New Data Which Highlights The Reduction In The Percentage Of Days With Hereditary Angioedema (HAE) Symptoms Among Young Children Initiating Berotralstat In The Apex-P Trial, And The Broad Safety And Efficacy Outcomes Observed Across All Age Groups Of Patients Taking Orladeyo To Prevent HAE Attacks

Management

TLSI

TriSalus Life Sciences  Appoints David Patience As CFO, Effective Jul. 1

PLBY Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) (the "Company" or "PLBY Group"), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today announced that the Company will be included in the Russell Microcap&#xAE; Index at the conclusion of the 2025 Russell U.S. Indexes annual reconstitution, and will be in effect as of the opening of the U.S. stock market on June 30, 2025.

PLBY

PLBY Group To Be Included In Russell Microcap Index At Conclusion Of 2025 Russell U.S. Indexes Annual Reconstitution

CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share. The warrants will be exercisable immediately following the issuance date and have a term of three and one-half years from the issuance date. The offering is expected to close on or about June 2, 2025, subject to the satisfaction of customary closing conditions.

Offerings

CLGN

CollPlant Raises $3.6M in Stock and Warrant Deal to Fund Regenerative Medicine Growth

Press Releases

KindlyMD(TM) Announces Contract with United Healthcare Insurance, the Largest Health Insurer in the United States

KindlyMD(TM) Announces $500,000 Share Repurchase Program

Contracts

KindlyMD(R) Announces New Partnership With Cigna Healthcare to Further Expand Patient Care Accessibility

KindlyMD(R) Announces Third Quarter 2024 Financial Results

KindlyMD(R) Opens New Integrated Behavioral Health Clinic on the Ogden Regional Medical Center Campus

David Bailey and Bitcoin-Native Holding Company Nakamoto Announce Merger with KindlyMD® to Establish Bitcoin Treasury

Stocks Under $5 to Watch: KDLY, PRSO, NXTT, GRYP, YHC Lead Headlines with Bitcoin, AI, and Semiconductor Catalysts

KindlyMD® Shareholders Approve Proposed Merger with Nakamoto Holdings

Nakamoto Holdings, Kindly MD, and Anchorage Digital Form Strategic Bitcoin Treasury Partnership

KindlyMD® Announces NASDAQ Ticker Symbol Change to 'NAKA' Effective May 23, 2025

Comments

Kindly MD Inc

Notizie

Ultime notizie per Kindly MD Inc (NASDAQ:KDLY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO